PR 15

Drug Profile

PR 15

Alternative Names: Dimeric glycoprotein VI-Fc; GPVI-Fc; PR-15; Revacept

Latest Information Update: 25 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Corimmun
  • Developer advanceCor
  • Class Antiarrhythmics; Antiplatelets; Antithrombotics; Heart failure therapies; Platelet membrane glycoproteins; Vascular disorder therapies
  • Mechanism of Action Platelet membrane glycoprotein VI inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute coronary syndromes; Stroke

Most Recent Events

  • 10 Feb 2016 Phase-II development is ongoing in Germany and United Kingdom (NCT01645306)
  • 30 Apr 2013 Phase-II clinical trials in Acute coronary syndromes in Germany (IV)
  • 30 Apr 2013 Phase-II clinical trials in Stroke in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top